Subcutaneous formulation off to an encouraging start; R&D pipeline progressing well
13/08/20 -"Despite being slightly impacted by COVID-19 in Q2, Darzalex continued to gain share in the multiple myeloma market. Given the encouraging launch of the subcutaneous formulation, we anticipate a ..."
Pages
50
Language
English
Published on
13/08/20
You may also be interested by these reports :
06/10/25
Over the week ending 3 October, equity markets delivered another strong performance. In Europe, the STOXX 600 rose 2.9%, driven by a massive rebound ...
03/10/25
We have materially upgraded our earnings estimates for UCB, keeping in view the vigorous uptake of the immunology drug Bimzelx, and a strong support ...
29/09/25
Genmab is strategically acquiring Merus to expand its late-stage portfolio with head and neck cancer treatments, addressing anticipated declines in ...
24/09/25
When we last pushed the Spanish blood plasma giant Grifols’ (BUY ; Spain) investment case in May 2024, investor confidence was close to its nadir, as ...